Website intended for a NZ health professional readership
The video of the fourth in our series of “The Popcorn Panels: Chatting about the Simpson report” is now available online.
Host and New Zealand Doctor|Rata Aotearoa editor Barbara Fountain chatted with panellists ProCare clinical director Allan Moffitt, health sector commentator Ian Powell and University of Auckland associate professor of health policy Tim Tenbensel.
A huge thank you to our panellists and for those who tuned in live last night!
A great discussion was had about the prospect of a new agency Health NZ, and how the country might operate with less, but more “super-sized DHBs”.
There was plenty of chat from the audience and thought-provoking questions!
You can see a video recording of the panel discussion here
Allan Moffitt
Allan is clinical director of ProCare Health PHO. Allan has previously worked in DHB planning and funding.
Tim Tenbensel
Tim is associate professor in health policy at The University of Auckland and is a keen observer of health systems at the local and national level. He is a regular contributor to New Zealand Doctor | Rata Aotearoa.
Ian Powell
Ian Powell is former executive director of the Association of Salaried Medical Specialists, a role he held for over 30 years. He is now a health commentator based in Otaihanga on the Kapiti Coast, and also writes for New Zealand Doctor | Rata Aotearoa.
There were four sessions in this series of “The Popcorn Panels: Chatting about the Simpson report”, watch the rest here
Watch Popcorn Panellists chatting about general practice and the Simpson report
Watch Popcorn Panellists chatting about the Simpson report and a Māori Health Authority
Watch Popcorn Panellists chatting about the Simpson report and PHOs
Another session is coming soon: watch out for “The Popcorn Panels - What can save pharmacy?” on 12 August, hosted by The Health Media and Pharmacy Today|Kaitiaki Rongoā o te Wā.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
